Loading...
OTCM
GBLX
Market cap81kUSD
Jul 31, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-99.94%
IPO
-100.00%
Name

GB Sciences Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
13.62%
Rev. gr., 5y
7.52%
Revenues
0k
054,5932,036,33100000000002,510,3643,454,5523,120,6200000
Net income
-1m
L-100.00%
-376,485-445,229-557,684-94,745-139,467-2,964,861-585,293-14,76436,150-655,955-7,722,755-6,771,335-9,909,830-22,974,190-23,653,165-11,635,465-4,782,9011,657,101-2,631,569,125,194-1,361,677
CFO
-976k
L-36.10%
-339,574-318,424-233,344-18,269-128,734-541,585-183,660-96,518-37,447-213,650-3,545,583-3,564,008-4,468,995-12,247,994-9,239,876-4,479,713-2,185,220-1,866,154-1,526,861-975,698
Earnings
Aug 28, 2025

Profile

GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
IPO date
Dec 22, 2003
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
1,421
1,734
Unusual Expense (Income)
NOPBT
(1,421)
(1,734)
NOPBT Margin
Operating Taxes
2,631,565,000
Tax Rate
NOPAT
(1,421)
(2,631,566,734)
Net income
(1,362)
-100.00%
(2,631,569,125)
-158,805,696.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
236
1,483
BB yield
-8.87%
-23.04%
Debt
Debt current
1,437
1,396
Long-term debt
322
Deferred revenue
Other long-term liabilities
Net debt
1,747
1,286
Cash flow
Cash from operating activities
(976)
(1,527)
CAPEX
(32)
Cash from investing activities
320
(32)
Cash from financing activities
558
1,435
FCF
199,589,709
(2,831,157,990)
Balance
Cash
12
110
Long term investments
Excess cash
12
110
Stockholders' equity
(110,026)
(108,667)
Invested Capital
106,471
104,697
ROIC
ROCE
39.98%
43.68%
EV
Common stock shares outstanding
396,729
357,721
Price
0.01
-62.78%
0.02
-35.94%
Market cap
2,658
-58.72%
6,439
-27.86%
EV
4,405
7,725
EBITDA
(1,421)
(1,672)
EV/EBITDA
Interest
219
179
Interest/NOPBT